ArticleChina CDC weekly2026
Interpretation of China's Action Plan for Viral Hepatitis Prevention and Care (2025-2030).
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis is a major public health concern in China. In alignment with the World Health Organization (WHO) 2016 global strategy to eliminate viral hepatitis as a public health threat by 2030, and in further implementation of the "Healthy China 2030" initiative, the National Disease Control and Prevention Administration, together with eight other government departments, jointly issued China's Action Plan for Viral Hepatitis Prevention and Care (2025-2030) ("Action Plan"). Compared with the 2017-2020 Plan, the new Action Plan introduced, for the first time, explicit 80% diagnosis and treatment coverage targets for both hepatitis B virus (HBV) and hepatitis C virus (HCV), replacing the 1% hepatitis B surface antigen (HBsAg) prevalence target for children under five with a more ambitious 0.2% target and shifting from passive case-finding to active screening. The Action Plan outlines 6 specific targets and 13 key measures across 5 strategic areas: strengthening vaccination, enhancing comprehensive prevention, expanding testing and surveillance, improving treatment services, and strengthening health education and social support. Key challenges include a large population living with viral hepatitis, a high disease burden from cirrhosis and liver cancer, persistent care cascade gaps, fragmented service delivery, and insufficient dedicated funding. Priority actions include improving information systems for whole-course management, optimizing service delivery through medical-prevention coordination, promoting integrated multidisease-prevention efforts, and increasing resource investment, including exploring inclusion of viral hepatitis services in the basic public health service package. This Action Plan provides a strategic roadmap for China to systematically advance toward the global 2030 elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.